Wegovy 1mg weight loss: what this dose is for and what to expect

What STEP 1 tells us about semaglutide at different doses

The STEP 1 trial is the cornerstone of the clinical case for Wegovy in weight management. It randomised adults with obesity or overweight plus a weight-related condition to 2.4mg semaglutide or placebo, alongside lifestyle support, for 68 weeks. Average weight reduction at 2.4mg came out at around 15%, a figure that sits comfortably above anything seen with older medicines. But that result belongs to the maintenance dose. Participants spent only four weeks at each titration step, meaning 1mg was a waypoint rather than a destination.

What the data show is that weight loss builds progressively as doses rise. Some appetite suppression is present from the early steps; gastric emptying begins to slow from the first injection. By the time a person reaches 1mg, they may already notice hunger quietening between meals. That experience is real and worth acknowledging. Even so, the prescribing schedule is constructed around the full 2.4mg target, titration exists to give the body time to adjust, not to park people at a lower dose indefinitely.

The NHS semaglutide information page describes the titration schedule and what to expect at each stage, and is a useful companion to any prescription. If you want to understand where the 1mg step fits within the complete dose journey, the overview at how Wegovy doses work maps the full progression.

Where 1mg sits in the Wegovy dose schedule (and why the steps matter

Wegovy's licensed titration pathway runs 0.25mg for four weeks, then 0.5mg, 1.0mg, 1.7mg and finally 2.4mg) each held for approximately four weeks before the prescriber moves the dose upward. If you are curious about what wegovy 0.25 weight loss looks like at that opening stage, the dedicated page sets out what people typically experience before the first step up. The approved higher-dose pathway, following the MHRA's 2026 authorisation of a dedicated 7.2mg pen, extends the schedule further for eligible adults with a BMI of 30 or above who have not reached their target at 2.4mg.

The step from 0.5mg to 1mg is often when patients first notice a more pronounced effect on appetite. It is also a common point for GI side effects to resurface briefly. Nausea, looser stools or indigestion after a dose increase are not a sign something has gone wrong, they are the expected pharmacological consequence of a step up, and most people find they settle within the first couple of weeks. Staying well hydrated and eating smaller, lower-fat meals can help. Specific advice on timing and management belongs with your prescriber and the patient information leaflet, not a content page.

If you missed an injection at this or any other dose, the guidance on missed Wegovy doses covers what to do next. And if you are curious about the step just below, the 0.5mg page sets out what that earlier stage involves.

Eligibility, the prescription route, and what 1mg weight loss actually looks like

Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition, hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease among them. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine approval; a prescriber reviews the full clinical picture, including any contraindications or interactions.

On the NHS, access to Wegovy sits within specialist weight management services and involves a waiting list. Private prescription through a regulated UK pharmacy is the alternative for people who do not meet NHS criteria or do not want to wait. Either way, the medicine requires a valid prescription following clinical assessment, no exceptions. If you are weighing up what private treatment costs and what that price genuinely covers, the Wegovy pricing page sets it out plainly.

Practically speaking: at 1mg, many people report a noticeable reduction in the pull of snack cravings and a smaller appetite at main meals. Weight loss is happening, though the rate typically accelerates as doses continue to rise toward 2.4mg. If a patient's weight loss falls below 5% after six months on the maintenance dose, NICE guidance recommends reviewing whether to continue, a decision the prescriber makes, not the patient alone.

The Wegovy treatment overview covers the medicine's full licensed profile, and exploring the broader treatment options may be useful if you are still deciding whether an injectable or oral route suits you better. Our clinical team reviews every consultation personally, a real prescriber, same day.